These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 32950711)

  • 1. Comparative outcomes of cefazolin versus antistaphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post hoc analysis of a prospective multicentre French cohort study.
    Lecomte R; Bourreau A; Deschanvres C; Issa N; Le Turnier P; Gaborit B; Chauveau M; Leroy AG; Le Tourneau T; Caillon J; Camou F; Boutoille D
    Clin Microbiol Infect; 2021 Jul; 27(7):1015-1021. PubMed ID: 32950711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antistaphylococcal penicillins vs. cefazolin in the treatment of methicillin-susceptible Staphylococcus aureus infective endocarditis: a quasi-experimental monocentre study.
    Lefèvre B; Hoen B; Goehringer F; Sime WN; Aissa N; Alauzet C; Jeanmaire E; Hénard S; Filippetti L; Selton-Suty C; Agrinier N;
    Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2605-2616. PubMed ID: 34383175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins.
    Li J; Echevarria KL; Traugott KA
    Pharmacotherapy; 2017 Mar; 37(3):346-360. PubMed ID: 28035690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of trials comparing cefazolin to antistaphylococcal penicillins in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia.
    Rindone JP; Mellen CK
    Br J Clin Pharmacol; 2018 Jun; 84(6):1258-1266. PubMed ID: 29600576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A large retrospective cohort study of cefazolin compared with flucloxacillin for methicillin-susceptible Staphylococcus aureus bacteraemia.
    Davis JS; Turnidge J; Tong S
    Int J Antimicrob Agents; 2018 Aug; 52(2):297-300. PubMed ID: 29499317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of empirical antibiotic treatments in methicillin-susceptible Staphylococcus aureus infective endocarditis: A post hoc analysis of a prospective French cohort study.
    Lecomte R; Deschanvres C; Bourreau A; Ruffier d'Epenoux L; Le Turnier P; Gaborit B; Chauveau M; Michel M; Le Tourneau T; Bémer P; Corvec S; Boutoille D
    Int J Infect Dis; 2024 May; 142():106989. PubMed ID: 38428479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal treatment of MSSA bacteraemias: a meta-analysis of cefazolin versus antistaphylococcal penicillins.
    Bidell MR; Patel N; O'Donnell JN
    J Antimicrob Chemother; 2018 Oct; 73(10):2643-2651. PubMed ID: 30085140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia.
    Weis S; Kesselmeier M; Davis JS; Morris AM; Lee S; Scherag A; Hagel S; Pletz MW
    Clin Microbiol Infect; 2019 Jul; 25(7):818-827. PubMed ID: 30928559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-treatment outcomes of ceftriaxone versus antistaphylococcal penicillins or cefazolin for definitive therapy of methicillin-susceptible Staphylococcus aureus bacteremia.
    Yetmar ZA; Khodadadi RB; Go JR; Chesdachai S; Abu Saleh OM
    Eur J Clin Microbiol Infect Dis; 2023 Apr; 42(4):423-430. PubMed ID: 36800065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cefazolin versus anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bacteraemia: a narrative review.
    Loubet P; Burdet C; Vindrios W; Grall N; Wolff M; Yazdanpanah Y; Andremont A; Duval X; Lescure FX
    Clin Microbiol Infect; 2018 Feb; 24(2):125-132. PubMed ID: 28698037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of cefazolin versus antistaphylococcal penicillins for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a systematic review and meta-analysis.
    Shi C; Xiao Y; Zhang Q; Li Q; Wang F; Wu J; Lin N
    BMC Infect Dis; 2018 Oct; 18(1):508. PubMed ID: 30305037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefazolin vs. anti-staphylococcal penicillins for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections in acutely ill adult patients: Results of a systematic review and meta-analysis.
    Lee BJ; Wang SK; Constantino-Corpuz JK; Apolinario K; Nadler B; McDanel JS; Scheetz MH; Rhodes NJ
    Int J Antimicrob Agents; 2019 Mar; 53(3):225-233. PubMed ID: 30476572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 'Comparative outcomes of cefazolin versus anti-staphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post-hoc analysis multicentre French cohort study'-author's reply.
    Lecomte R; Deschanvres C; Coudol S; Wargny M; Camou F; Boutoille D
    Clin Microbiol Infect; 2021 Aug; 27(8):1180-1181. PubMed ID: 33813113
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: 'Comparative outcomes of cefazolin versus anti-staphylococcal penicillins in methicillin-susceptible Staphylococcus aureus infective endocarditis: a post-hoc analysis multicentre French cohort study' by Lecomte et al.
    Buis DTP
    Clin Microbiol Infect; 2021 Aug; 27(8):1179. PubMed ID: 33581355
    [No Abstract]   [Full Text] [Related]  

  • 15. Antistaphylococcal penicillins versus cephalosporins for definitive treatment of meticillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis.
    Vardakas KZ; Apiranthiti KN; Falagas ME
    Int J Antimicrob Agents; 2014 Dec; 44(6):486-92. PubMed ID: 25311850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary use of cefazolin for MSSA infective endocarditis: analysis of a national prospective cohort.
    Herrera-Hidalgo L; Muñoz P; Álvarez-Uría A; Alonso-Menchén D; Luque-Marquez R; Gutiérrez-Carretero E; Fariñas MDC; Miró JM; Goenaga MA; López-Cortés LE; Angulo-Lara B; Boix-Palop L; de Alarcón A;
    Int J Infect Dis; 2023 Dec; 137():134-143. PubMed ID: 37926195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections.
    Rao SN; Rhodes NJ; Lee BJ; Scheetz MH; Hanson AP; Segreti J; Crank CW; Wang SK
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5232-8. PubMed ID: 26077253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective Evaluation of the Association of Oxacillin MIC on Acute Treatment Outcomes with Cefazolin and Antistaphylococcal Penicillins in Methicillin-Susceptible Staphylococcus aureus Bacteremia.
    Hess KA; Kooda K; Shulha JA; Mara K; Go JR; Fida M; DeSimone DC; Stevens RW
    J Clin Microbiol; 2023 Apr; 61(4):e0003923. PubMed ID: 36988505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation.
    Lee BJ; Rao SN; Wang SK; Lee JY; Lakada IY; Gilbert EM; Barr VO; Postelnick MJ; Sutton SH; Zembower TR; Bolon M; Scheetz MH; Rhodes NJ
    Int J Antimicrob Agents; 2017 May; 49(5):650-654. PubMed ID: 28279787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefazolin versus cloxacillin as definitive antibiotic therapy for methicillin-susceptible Staphylococcus aureus spinal epidural abscess: a retrospective cohort study.
    Bai AD; Findlater A; Irfan N; Singhal N; Loeb M
    Int J Antimicrob Agents; 2021 Nov; 58(5):106429. PubMed ID: 34469802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.